In-vitro and in-silico assessment of thiazole-thiazolidinone derivatives as selective inhibitors of urease and α-glucosidase.

IF 3.2 4区 医学 Q3 CHEMISTRY, MEDICINAL
Future medicinal chemistry Pub Date : 2024-12-01 Epub Date: 2024-12-08 DOI:10.1080/17568919.2024.2432303
Yousaf Khan, Rafaqat Hussain, Wajid Rehman, Shoaib Khan, Aneela Maalik, Tayyiaba Iqbal, Tariq Aziz, Muhammad Irfan Afridi, Metab Alharbi, Abdullah F Alasmari
{"title":"<i>In-vitro</i> and <i>in-silico</i> assessment of thiazole-thiazolidinone derivatives as selective inhibitors of urease and α-glucosidase.","authors":"Yousaf Khan, Rafaqat Hussain, Wajid Rehman, Shoaib Khan, Aneela Maalik, Tayyiaba Iqbal, Tariq Aziz, Muhammad Irfan Afridi, Metab Alharbi, Abdullah F Alasmari","doi":"10.1080/17568919.2024.2432303","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Current research work aims to synthesize hybrid compounds with a thiazole-thiazolidinone structure, as potent inhibitors of urease and α-glucosidase enzymes.</p><p><strong>Materials and methods: </strong>These compounds were characterize through<sup>1</sup>HNMR,<sup>13</sup>CNMR and HREI-MS techniques. These compounds were also evaluated for their potential to inhibit urease and α-glucosidase enzymes for the treatment of urinary tract infections (UTIs) and diabetes treatments. Moreover, molecular docking and ADMET analysis was carried out to confirm biological outcomes.</p><p><strong>Results and conclusion: </strong>Compounds-4 (IC<sub>50</sub> = 1.80 ± 0.80 and 3.61 ± 0.59 μM against urease and α-glucosidase, respectively) exhibited significant effectiveness in inhibiting the activity of both enzymes in comparison to the conventional inhibitors thiourea and acarbose. Molecular docking experiments showed that potent compounds exhibited favorable binding orientations in the active sites of urease and α-glucosidase playing a pivotal role in inhibition profile of these compounds. These compounds were also investigated for their drug likeness and were found with desirable attributes for pharmaceutical development. Based on the findings of this research, these compounds have the potential to be developed into effective anti-diabetic and anti-urease treatments in the future.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2627-2636"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2432303","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Current research work aims to synthesize hybrid compounds with a thiazole-thiazolidinone structure, as potent inhibitors of urease and α-glucosidase enzymes.

Materials and methods: These compounds were characterize through1HNMR,13CNMR and HREI-MS techniques. These compounds were also evaluated for their potential to inhibit urease and α-glucosidase enzymes for the treatment of urinary tract infections (UTIs) and diabetes treatments. Moreover, molecular docking and ADMET analysis was carried out to confirm biological outcomes.

Results and conclusion: Compounds-4 (IC50 = 1.80 ± 0.80 and 3.61 ± 0.59 μM against urease and α-glucosidase, respectively) exhibited significant effectiveness in inhibiting the activity of both enzymes in comparison to the conventional inhibitors thiourea and acarbose. Molecular docking experiments showed that potent compounds exhibited favorable binding orientations in the active sites of urease and α-glucosidase playing a pivotal role in inhibition profile of these compounds. These compounds were also investigated for their drug likeness and were found with desirable attributes for pharmaceutical development. Based on the findings of this research, these compounds have the potential to be developed into effective anti-diabetic and anti-urease treatments in the future.

噻唑-噻唑烷酮衍生物作为脲酶和α-葡萄糖苷酶选择性抑制剂的体外和计算机评价。
目的:目前的研究工作旨在合成具有噻唑-噻唑烷酮结构的杂化化合物,作为脲酶和α-葡萄糖苷酶的有效抑制剂。材料和方法:通过1hnmr、13CNMR和HREI-MS对化合物进行了表征。这些化合物还被评估其抑制脲酶和α-葡萄糖苷酶治疗尿路感染(uti)和糖尿病的潜力。此外,还进行了分子对接和ADMET分析,以确认生物学结果。结果与结论:化合物-4对脲酶和α-葡萄糖苷酶的IC50分别为1.80±0.80和3.61±0.59 μM,对脲酶和α-葡萄糖苷酶的抑制效果优于常规抑制剂硫脲和阿卡波糖。分子对接实验表明,有效化合物在脲酶和α-葡萄糖苷酶的活性位点表现出良好的结合取向,对这些化合物的抑制作用起关键作用。还研究了这些化合物的药物相似性,并发现它们具有用于药物开发的理想属性。基于本研究的发现,这些化合物在未来有可能被开发成有效的抗糖尿病和抗脲酶治疗药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信